iTeos shares its discovery platform for partnerships and R&D collaborations to develop innovative immunomodulators targeting the tumor microenvironment.
Our expertise and know-how in tumor biology and drug discovery have enabled us to develop novel immunomodulators very efficiently. We collaborate with charities and top-tier academic or industrial partners to identify novel immunotherapies.
Deal structures are tailored to build a win-win relationship in order to repurpose an existing drug candidate in immuno-oncology or to start a drug discovery program with a new target. Through these partnerships, we can provide expertise in drug discovery and proprietary know-how in addition to funding.